SNOA

Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K Summary

Business Context and Reporting Period

Company: Sonoma Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Fiscal Year Ended: March 31, 2026
Business Overview: A global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for wound care, dermatology, eye care, podiatry, animal health, and surface disinfection. The company manufactures all products at its facility in Zapopan, Mexico, and sells directly or via partners in over 55 countries.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 37% year-over-year, driven primarily by a 117% surge in U.S. sales ($5.67M vs. $2.61M) due to expanded OTC product sales and new distributor relationships. Europe and Asia also saw 25% growth.
• Expense Management: Selling, General, and Administrative (SG&A) expenses increased only 3% ($7.61M vs. $7.36M) despite revenue growth, improving SG&A as a percentage of revenue from 52% to 39%. Research and Development (R&D) expenses rose 25% to $2.27M to support new product launches.
• Liquidity Position: Cash reserves decreased by approximately $3.0 million during the year, primarily due to operating losses and increased prepaid expenses. However, the company reduced its net loss per share significantly.
• Geographic Mix: International revenue (outside the U.S.) accounted for approximately 71% of total revenue in 2026, down from 82% in 2025, reflecting the strong U.S. growth.

Guidance, Outlook, Risks, and Unusual Items

• Recent Capital Raise: In a subsequent event (April 2026), the company completed a public offering with Dawson James Securities, Inc., raising approximately $3.57 million in net proceeds. Management believes this, combined with existing cash, is sufficient to fund operations for the next 12 months.
• Product Launches: Recent milestones include the U.S. retail launch of burn relief hydrogel in CVS and Walmart, FDA registration under MoCRA for facial sprays, and new distribution agreements with Medline Industries and Persón & Covey.
• Significant Tax Liability: The company faces a substantial potential tax liability in Mexico related to intercompany loans and technical assistance fees. As of March 31, 2026, the Mexican subsidiary owes approximately $54.9 million in principal, technical assistance, and accrued interest. If forgiven or converted to equity, this could trigger a ~$16.5 million income tax liability and ~$5.6 million withholding tax. The company currently has no ability to claim foreign tax credits due to U.S. net operating losses.
• Customer Concentration: Customer C represented 15% of net revenues in 2026. Customer A and C represented 12% and 19% of accounts receivable, respectively.
• Regulatory Risks: The company is subject to FDA and EU Medical Device Regulation (MDR) compliance. A proposed FDA rule could require new 510(k) applications for certain wound care products.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.57M recent capital raise against the $3.93M operating cash burn rate to confirm the 12-month liquidity assertion.
• Mexico Tax Exposure: Review the specific legal and tax strategies being employed to mitigate the ~$22 million potential tax liability associated with intercompany debt in Mexico.
• Customer Concentration: Assess the stability of relationships with top customers (specifically Customer C) given their significant contribution to revenue and receivables.
• Regulatory Compliance: Monitor the status of the FDA's proposed rule on wound dressings and the company's progress in transitioning remaining products to EU MDR standards.
• Dilution Impact: Evaluate the impact of the recent offering (including pre-funded warrants and warrants) on existing shareholder equity and future dilution.